Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Eltrombopag restores tri-lineage hematopoiesis in refractory severe aplastic anemia which can be sustained on discontinuation of drug

    ... aplastic anemia (SAA) remain pancytopenic despite immunosuppressive therapy. We have previously demonstrated that eltrombopag has ... patients with robust near-normalization of blood counts had drug discontinued at a median of 28.5 months after entry (range 9 to 37), and ...

    Research Article last updated 01/07/2014 - 12:22pm.

  2. Eltrombopag Added to IST Yields Encouraging Results

    ... that stimulating remaining stem cells with a drug that mimics the actions of a natural growth substance for marrow stem ... frequency in patients who had not adequately responded to immunosuppressive therapy (IST). These refractory patients were ...

    Interview last updated 05/24/2017 - 7:44am.

  3. Judi Wilkinson

    ... Treatment Related Links Immunosuppressive drug therapy Bone marrow transplant ...

    "Like You" Patient Story last updated 06/01/2017 - 10:33am.

  4. Eltrombopag in aplastic anemia

    ... The treatment of aplastic anemia is currently with immunosuppressive therapy (IST) with anti-thymocyte globulin (ATG) and ... refractory to IST. There is evidence that this drug works by directly stimulating marrow stem and progenitor cells thereby ...

    Research Article last updated 03/02/2015 - 12:51pm.

  5. Stem Cell Transplant from Unrelated Donor in Patients with Severe Aplastic Anemia: Indications, Donor Selection, Conditioning, GVHD Prophylaxis

    Journal Title:  Curr Drug Targets Primary Author:  ... marrow. Historically the two treatments option have been immunosuppressive therapy (IST) and bone marrow transplantation (HSCT) ...

    Research Article last updated 03/03/2015 - 11:27am.

  6. Briana Donis

    ... Treatment Immunosuppressive therapy was the first course of treatment, but it didn’t ... Links Immunosuppressive drug therapy Bone marrow transplant ...

    "Like You" Patient Story last updated 04/28/2017 - 1:56pm.

  7. How much? How frequent? How long? A clinical guide to new therapies in myelodysplastic syndromes.

    ... of the disease. Three drugs are now specifically Food and Drug Administration-approved for treatment of MDS: (1) azacitidine , ... results with each of these agents, plus results with immunosuppressive therapy, are reviewed to guide clinical decision making. ...

    Research Article last updated 10/11/2011 - 5:58pm.

  8. Ricky Smith, Jr.

    ... Treatment Related Links Immunosuppressive drug therapy Prednisone Eculizumab ...

    "Like You" Patient Story last updated 04/05/2017 - 1:27pm.

  9. A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation

    ... prior to the start of therapy and on the first day of study drug administration. Exclusion Criteria:  ... within 60 days of the first dose of AG-120, or subjects on immunosuppressive therapy post HSCT at the time of screening, or with ...

    Clinical Trial last updated 02/22/2017 - 11:21am.

  10. MEDALIST Trial

    ... syndromes (MDS) Associated Drug(s):  Luspatercept ... such as lenalidomide ], hypomethylating agents, or immunosuppressive therapy [IST]).      Previously treated with either ...

    Clinical Trial last updated 02/22/2017 - 11:42am.